OMEROS CORP (OMER)
Health Care · NASDAQ
A clinical-stage biotech company commercializing complement-pathway inhibitors for rare hematologic and immune diseases, with FDA-approved YARTEMLA for stem cell transplant complications and a $240M asset sale of its lead MASP-3 program to Novo Nordisk.
What OMEROS CORP does
Omeros is a biotechnology company discovering and developing first-in-class protein and small-molecule therapeutics targeting complement-mediated diseases, cancers, and addictive or compulsive disorders. The company recently commercialized YARTEMLA (narsoplimab-wuug), the first FDA-approved therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), which began sales in January 2026. In November 2025, Omeros completed the sale of its lead MASP-3 inhibitor zaltenibart to Novo Nordisk for $240 million upfront plus up to $1.8 billion in additional milestone payments and royalties, while retaining rights to small-molecule MASP-3 programs in ophthalmology, neurology, and other indications.
Themes: ["Complement pathway inhibition"]
Fundamentals
- Price$10.27 as of 2026-07-09 close
- Market cap$748M as of 2026-07-10
- 1-year return+203.8% as of 2026-07-09 close
- P/E8.68 as of 2026-07-10
- Net margin+566.7% as of 2026-07-10
- Gross margin+94.1% as of 2026-07-10
- ROE+107.5% as of 2026-07-10
- Debt / equity21.55 as of 2026-07-10
- Revenue CAGR (3y)+4.4% SEC XBRL
- Beta2.59 as of 2026-07-10
Key risks (from latest filing)
["YARTEMLA commercialization success uncertain – newly approved product with limited market data and competition from other complement inhibitors; reimbursement and adoption rates in TA-TMA indication remain unproven."]
Competitors & peers
- Alexion Pharmaceuticals (ALXN) – complement inhibitors including Ultomiris (pegcetacoplan)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.